CJC-1295 DAC dosage protocols leverage this long-acting growth hormone-releasing hormone (GHRH) analog’s unique albumin-binding technology, which extends its half-life to approximately 6–8 days. By stimulating pulsatile growth hormone (GH) release while preserving natural GH rhythms, CJC-1295 DAC can elevate GH levels 2–10 fold and IGF-1 levels 1.5–3 fold in human studies. Benefits may include enhanced muscle growth and recovery, improved fat metabolism, better sleep quality, and anti-aging effects through sustained GH/IGF-1 axis activation. This educational protocol presents a once-weekly subcutaneous approach using a practical dilution for clear insulin-syringe measurements.
| Phase | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–12 | 2,000 mcg (2 mg) | 100 units (1.00 mL) |
Frequency: Inject once weekly subcutaneously, preferably in the evening before bed to align with natural nocturnal GH surges. The peptide’s extended half-life (~6–8 days) supports weekly administration without significant loss of activity between doses.
Reconstitution Steps
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
CJC-1295 DAC is a modified 30-amino-acid GHRH analog conjugated to a Drug Affinity Complex (DAC) that covalently binds to serum albumin after injection. This albumin binding dramatically extends the peptide’s half-life from minutes to approximately 6–8 days, enabling once-weekly dosing. CJC-1295 binds to GHRH receptors on pituitary somatotrope cells, amplifying GH synthesis and pulsatile release. Importantly, it elevates basal GH levels while preserving the natural rhythm of GH pulses — the frequency and amplitude remain intact. Clinical trials demonstrate sustained 2–10 fold increases in GH and 1.5–3 fold increases in IGF-1, with elevated IGF-1 persisting for up to 28 days after multiple doses.